Crossmark

Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease

Crossref DOI link: https://doi.org/10.1186/s13063-022-06562-9

Published Online: 2022-09-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vermeulen, Emma A. https://orcid.org/0000-0002-2189-6382
Eelderink, Coby

Hoekstra, Tiny

van Ballegooijen, Adriana J.

Raijmakers, Pieter

Beulens, Joline W.

de Borst, Martin H.

Vervloet, Marc G.
Funding

Funding for this research was provided by:

Nierstichting (16TKI02 (under Health Holland grant no. LSHM17034-HSGF))
License Information

Text and Data Mining valid from 2022-09-12

Version of Record valid from 2022-09-12
More Information

Article History

Received: 29 November 2021

Accepted: 18 July 2022

First Online: 12 September 2022

Declarations

:

: This study is approved by the medical research ethics committee (MREC, or in Dutch METC) of the VUmc (18 October 2019, reference number 2019.333, NL69613.029.19) and by the competent authority (CA), the Central Committee on Research Involving Human Subjects (in Dutch CCMO) the 12 November 2019.Written, informed consent to participate will be obtained from all participants as explained in the “” section.

: A model informed consent form is available on request.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below